You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
东阳光药(01558.HK)抗丙肝新药磷酸依米他韦上市申请获国家药监局受理
格隆汇 09-11 21:13

格隆汇9月11日丨东阳光药(01558.HK)公告,公司自主研究及开发的抗丙型肝炎新药磷酸依米他韦已经获得国家药品监督管理局受理,受理号:CXHS1900030国。该新药为公司首个获得受理的国家1类新药,同时也是将在中国国内实现商业化的首批国产自研直接抗病毒药物。

未来该药品如顺利通过上市审评审批,将成为公司在抗丙肝治疗领域的主打产品一,进一步丰富公司的产品组合。公司也将继续推动新药研发,致力于为广大患者提供质价双优的用药选择。

公告为公司刊发自愿性公告,目的是使投资者了解集团最新业务发展情况,并不含有关于使用任何药物、外科设备、治疗或口服产品的广告或意图。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account